Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099060 | 0.94 | HPGD (0.44) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| Potassium Ion SCHEMBL6247341 | 0.94 | USP2 (0.44) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL16465836 | 0.85 | USP2 (0.42) | USP2SMN1; SMN2GPR119MEN1KMT2A | |
| SCHEMBL24673913 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL10253506 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL24102957 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL30897992 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL513246 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL7972047 | 0.81 | GRM5 (0.47) | USP2SMN1; SMN2GRM5ESR2ADORA1 | |
| SCHEMBL106354 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2GRM5ESR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025036453-A1 | EGFR MUTATION INHIBITORS AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2025-02-20 | — | — | WO | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-2531506-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | Intervet International B.V. (NL) | 2012-12-12 | — | — | EP | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011095581-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | INTERVET INTERNATIONAL B.V. (NL) | 2011-08-11 | — | — | WO | disclosed |
| EP-1515969-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-1880996-A1 | Spiroindolinepiperidine derivatives | Syngenta Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1515969-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | Syngenta Limited (GB) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106457-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | USP2 32/4885SMN1; SMN2 3149/4885GRM5 4382/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GRM5 2626/4885 |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | USP2 4596/4885SMN1; SMN2 935/4885GRM5 3519/4885 |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | USP2 4427/4885SMN1; SMN2 3833/4885GRM5 1691/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GRM5 2626/4885 |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | RECQL, OPRD1, NCAPD3 | USP2 4549/4885SMN1; SMN2 1132/4885GRM5 3362/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GRM5 2626/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GRM5 2626/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GRM5 2626/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GRM5 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.